Stock price when the opinion was issued
PBH is up 40% from seven years ago, but up 145% from exactly eight years ago. It is up 9% this year, nine percentage points ahead of the TSX. None of these returns include dividends. It is up 60% since it was added to the 5i Balanced Portfolio. Now, these are not 'stellar' returns, but consensus calls for 20% growth next year, higher than its valuation multiple. EPS has tripled since 2015, and, considering its stable and growing cash flow, we remain comfortable with it. We show IGM with a five-year return of -5.7% and PBH with a five-year return of 26.7%.
Unlock Premium - Try 5i Free
It is starting another 5 year plan to bring their sales up to $10 billion. This time it wants 80% of growth to be organic which is better since there will be more within its control. For this to happen it will need to increase revenue by 9 1/2%, more than the increase needed before. Although traction has not yet started, it can raise or hold prices since all are branded products. It is a good buy for the long term.
EPS of 54c beat estimates of 52c; revenue of $1.46B was marginally better than consensus. EBITDA of $121M was 6% better. Sales forecast was affirmed. EPS did slip from 64c last year. Revenue rose 2.2%, with specialty foods up 4.1%. Speciality foods has recovered nicely from its 4%+ contraction in the prior quarter, and showed 1% organic growth this quarter. The quarter was good and will likely be a relief for investors.
Unlock Premium - Try 5i Free
PBH has been on an investment cycle to expand production capacity in recent years, which has ramped up its capital investments meaningfully. That being said, the company has shown some early signs of a complete investment cycle and could be poised to reaccelerate growth in the near term. We think investors need some patience with PBH. A few catalysts that could make PBH interesting again include:
-Capital expenditures come down
-Organic growth accelerates
-Free cash flow recovers
We think a combination of these factors could lead to a significant multiple re-rate in share price.
Unlock Premium - Try 5i Free
She's been researching this name for a year, may soon initiate a position. Excellent management team, very long-term focus. Rational M&A and capital allocation strategy. Three recent acquisitions, plus lots of organic growth too. Really trying to grow US side. Capex spend on US manufacturing facility just about done, so cashflow will follow.
EPS of $1.05 beat estimates of 94c; revenue of $1.63B beat estimates of $1.60B. EBITDA of $148.7M beat estimates by 1.62%. 2025 guidance was raised to $7.20B+ from $7.15B+. Not a huge raise but it was a sigh of relief for investors. The dividend was not raised for the first year in 10. There remains some tariff concerns, though PBH says it is 'positioned well'. Sales rose 5.5% year over year. Specialty foods was very strong (+13%) but distribution was weak (-3.2%). But overall, good results.
Unlock Premium - Try 5i Free
Exposed to tariffs by only a small extent. What they are exposed to is the Canadian consumer, who might already be scaling back. It was one of his Top Picks last time around, mainly because added a lot of capacity in US. Concern around SBUX, its biggest client in the US; last quarter indicated this relationship is working. Interesting at these levels.
Going through significant transformation. Starting to realize benefits from new manufacturing capacity, can generate as much as $700M of incremental revenue. What excites him is that margin profile of this extra capacity is ~30%. This tells him that margins for the company as a whole will expand significantly over next 12-18 months.
(Analysts’ price target is $102.67)Going to reduce leverage. Trading at a multiple that doesn't reflect any of these positive developments. Significant insider buying. Yield is 4.3%.